Summary

Teva's global operations and recognition in association with many generic drugs of different classes and for different indications across many speciaties will be immensely helpful in marketing DiaPep277 worldwide. 

Analysis

Teva's global operations and recognition in association with many generic drugs of different classes and for different indications across many speciaties will be immensely helpful in marketing DiaPep277 worldwide.  Their steady income flow from larger market common drugs will give Andromeda Biotech the security needed while the market is being found and while the patients and physicians are being educated to consider the immediate use of DiaPep at the time of initial diagnosis of type 1 diabetes.  Although it would have been preferable for a company already long and positively associated with diabetes (Lilly, Novo, Sanofi-Aventis, etc.) to have partnered, Teva's support is likely to be very beneficial.

This author consults with leading institutions through GLG

Engage this author or other Healthcare experts
 
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.